GRI

GRI Bio, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies for gastrointestinal diseases. Headquartered in Seattle, Washington, the company operates through its wholly-owned subsidiary, Gri Biosciences, and concentrates on treatments that address significant unmet medical needs in gastroenterology. GRI Bio's lead product candidate is GRI-0621, an oral small molecule designed to treat celiac disease by preventing the breakdown of dietary gluten in the stomach, thereby reducing intestinal inflammation. The company's pipeline also includes programs targeting other gastrointestinal conditions such as inflammatory bowel disease. GRI Bio leverages proprietary technology platforms to identify and develop novel therapeutics that modulate immune responses in the gastrointestinal tract. In recent developments, the company has advanced its clinical programs, with GRI-0621 progressing through Phase 2 trials evaluating safety and efficacy in celiac disease patients. As a development-stage enterprise, GRI Bio maintains a lean operational structure while collaborating with research institutions and contract research organizations to advance its clinical studies. The company focuses its resources on regulatory pathways and clinical development activities aimed at bringing its gastrointestinal therapeutics to market, positioning itself within the specialized gastroenterology sector of the biopharmaceutical industry.